SARC Talk Journal Club is a podcast from SARC exploring the latest sarcoma research and clinical trials. Each episode features leading sarcoma experts reviewing new publications, discussing the evidence behind the findings, and exploring their impact on patient care, research, and the future of sarcoma treatment.
Stay informed on the science driving progress in bone and soft tissue sarcomas, emerging therapies, precision medicine, and clinical trial innovation through expert conversations that connect research with real-world practice.
In this episode of SARC Talk Journal Club, our panel reviews the SARC037 Phase 1/2 trial evaluating trabectedin plus low-dose irinotecan for patients with relapsed or refractory Ewing sarcoma. We discuss the study design, response rates, safety, and evidence that trabectedin may disrupt the EWS::FLI1 transcriptional program—a key driver of Ewing sarcoma. Explore what these findings could mean for future sarcoma treatment and research.
Join us for an evidence-based discussion of this important Ewing sarcoma study and the ongoing work to translate scientific discoveries into new treatment strategies.
📄 Read the study: https://pubmed.ncbi.nlm.nih.gov/41991689/ (https://pubmed.ncbi.nlm.nih.gov/41991689/)
16 Sept 2026
Brigimadlin vs Doxorubicin in Advanced Dedifferentiated Liposarcoma (DDLPS) - Brightline-1
In this episode of SARC Talk Journal Club, our panel discusses the Brightline-1 Phase II/III trial, evaluating brigimadlin (BI 907828) versus doxorubicin as first-line treatment for patients with advanced, MDM2-amplified dedifferentiated liposarcoma (DDLPS).
The panel reviews the study design, progression-free survival, objective response rates, safety findings, and translational data surrounding this novel MDM2-p53 antagonist. We explore what the results tell us about targeting the MDM2-p53 pathway and the ongoing challenges of developing new treatments for advanced DDLPS.
Join us for an expert discussion of this important sarcoma clinical trial and what the findings may mean for future liposarcoma research, targeted therapies, and clinical trial development.
Abstract: https://pubmed.ncbi.nlm.nih.gov/42268294/
12 Aug 2026
Zoledronic Acid and Chemotherapy in Ewing Sarcoma
In this episode of SARC Talk Journal Club, our panel discusses the EURO EWING 2012 Phase III trial, evaluating whether adding zoledronic acid to consolidation chemotherapy could improve outcomes for patients with Ewing sarcoma and Ewing-like sarcomas.
The panel reviews the study design, key findings, event-free and overall survival outcomes, and the implications of adding zoledronic acid to treatment. What can this trial teach us about translating promising preclinical findings into clinical practice?
Join us for an expert discussion of this important Ewing sarcoma clinical trial and what the results mean for future sarcoma research and treatment.
15 Jul 2026
Pimicotinib in Tenosynovial Giant Cell Tumor (TGCT)
In this episode of SARC Talk Journal Club, our panel discusses the MANEUVER Phase III trial published in The Lancet, evaluating pimicotinib versus placebo in patients with tenosynovial giant cell tumor (TGCT). We review the study design, efficacy, safety profile, and patient-reported outcomes while exploring what these findings could mean for the treatment of unresectable, symptomatic TGCT.
Join us as we examine the evidence behind this promising CSF-1R inhibitor and discuss its potential impact on clinical practice and future research in sarcoma.
24 Jun 2026
Cabozantinib and Temozolomide in Leiomyosarcoma
In this episode of SARC Talk Journal Club, we review the recent Lancet Oncology phase II trial evaluating the combination of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas. Our panel examines the study design, efficacy, safety profile, and clinical implications, discussing whether this combination represents a promising new treatment option and what questions remain for future research.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Host of SARC Talk Journal Club?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
